Coherus BioSciences Shares Rise 22% on Divestiture Agreement With Intas Pharmaceuticals

Dow Jones

2024-12-03

By Denny Jacob

Coherus BioSciences shares rose in premarket trading after the company disclosed a divested franchise that would bring in up to $588.4 million.

Shares were trading 22% higher at around $1.67. The stock is down 59% on the year.

The commercial-stage biopharmaceutical company said it reached an agreement with Intas Pharmaceuticals for the divestment of its Udenyca franchise. The agreement includes an upfront payment of $483.4 million and $75 million in potential sales milestone payments.

Coherus said it plans to use a portion of the payment to fully repay the entirety of its $230 million in existing convertible notes due in April 2026, among other expenses.

Chief Executive Denny Lanfear said the deal positions Coherus to maximize the opportunity ahead for Loqtorzi, an FDA-approved treatment for nasopharyngeal carcinoma.

The proposed transaction is expected to close by the end of the first quarter of 2025.

Write to Denny Jacob at denny.jacob@wsj.com

(END) Dow Jones Newswires

December 03, 2024 07:40 ET (12:40 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2488911662"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2488911662\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2488911662?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-03 20:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2488911662","market":"sh","top_or_hot":-1,"title":"Coherus BioSciences Shares Rise 22% on Divestiture Agreement With Intas Pharmaceuticals","media":"Dow Jones","content":"<html><body><font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Denny Jacob \n</p>\n<pre>\n \n</pre>\n<p>\n  Coherus BioSciences shares rose in premarket trading after the company disclosed a divested franchise that would bring in up to $588.4 million. \n</p>\n<p>\n  Shares were trading 22% higher at around $1.67. The stock is down 59% on the year. \n</p>\n<p>\n  The commercial-stage biopharmaceutical company said it reached an agreement with Intas Pharmaceuticals for the divestment of its Udenyca franchise. The agreement includes an upfront payment of $483.4 million and $75 million in potential sales milestone payments. \n</p>\n<p>\n  Coherus said it plans to use a portion of the payment to fully repay the entirety of its $230 million in existing convertible notes due in April 2026, among other expenses. \n</p>\n<p>\n  Chief Executive Denny Lanfear said the deal positions Coherus to maximize the opportunity ahead for Loqtorzi, an FDA-approved treatment for nasopharyngeal carcinoma. \n</p>\n<p>\n  The proposed transaction is expected to close by the end of the first quarter of 2025. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Denny Jacob at denny.jacob@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 03, 2024 07:40 ET (12:40 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones & Company, Inc.\n</p>\n</font></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>Coherus BioSciences Shares Rise 22% on Divestiture Agreement With Intas Pharmaceuticals</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCoherus BioSciences Shares Rise 22% on Divestiture Agreement With Intas Pharmaceuticals\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\">\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-12-03 20:40</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Denny Jacob \n</p>\n<pre>\n \n</pre>\n<p>\n  Coherus BioSciences shares rose in premarket trading after the company disclosed a divested franchise that would bring in up to $588.4 million. \n</p>\n<p>\n  Shares were trading 22% higher at around $1.67. The stock is down 59% on the year. \n</p>\n<p>\n  The commercial-stage biopharmaceutical company said it reached an agreement with Intas Pharmaceuticals for the divestment of its Udenyca franchise. The agreement includes an upfront payment of $483.4 million and $75 million in potential sales milestone payments. \n</p>\n<p>\n  Coherus said it plans to use a portion of the payment to fully repay the entirety of its $230 million in existing convertible notes due in April 2026, among other expenses. \n</p>\n<p>\n  Chief Executive Denny Lanfear said the deal positions Coherus to maximize the opportunity ahead for Loqtorzi, an FDA-approved treatment for nasopharyngeal carcinoma. \n</p>\n<p>\n  The proposed transaction is expected to close by the end of the first quarter of 2025. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Denny Jacob at denny.jacob@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 03, 2024 07:40 ET (12:40 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones & Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2488911662","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2488911662","pubTimestamp":1733229600,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Coherus BioSciences shares rose in premarket trading after the company disclosed a divested franchise that would bring in up to $588.4 million.Shares were trading 22% higher at around $1.67. The stock is down 59% on the year.The commercial-stage biopharmaceutical company said it reached an agreement with Intas Pharmaceuticals for the divestment of its Udenyca franchise. The agreement includes an upfront payment of $483.4 million and $75 million in potential sales milestone payments.Coherus said it plans to use a portion of the payment to fully repay the entirety of its $230 million in existing convertible notes due in April 2026, among other expenses.Chief Executive Denny Lanfear said the deal positions Coherus to maximize the opportunity ahead for Loqtorzi, an FDA-approved treatment for nasopharyngeal carcinoma.The proposed transaction is expected to close by the end of the first quarter of 2025.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4535":"淡马锡持仓","CHRS":"Coherus Biosciences"},"translate_title":"Coherus BioSciences股价因与Intas Pharmaceuticals达成剥离协议而上涨22%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CHRS":1},"content_text":"By Denny Jacob \n\n\n \n\n\n  Coherus BioSciences shares rose in premarket trading after the company disclosed a divested franchise that would bring in up to $588.4 million. \n\n\n  Shares were trading 22% higher at around $1.67. The stock is down 59% on the year. \n\n\n  The commercial-stage biopharmaceutical company said it reached an agreement with Intas Pharmaceuticals for the divestment of its Udenyca franchise. The agreement includes an upfront payment of $483.4 million and $75 million in potential sales milestone payments. \n\n\n  Coherus said it plans to use a portion of the payment to fully repay the entirety of its $230 million in existing convertible notes due in April 2026, among other expenses. \n\n\n  Chief Executive Denny Lanfear said the deal positions Coherus to maximize the opportunity ahead for Loqtorzi, an FDA-approved treatment for nasopharyngeal carcinoma. \n\n\n  The proposed transaction is expected to close by the end of the first quarter of 2025. \n\n\n \n\n\n  Write to Denny Jacob at denny.jacob@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 03, 2024 07:40 ET (12:40 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1}}}